Compare BCML & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCML | ENTA |
|---|---|---|
| Founded | 2004 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.6M | 382.7M |
| IPO Year | 2018 | 2012 |
| Metric | BCML | ENTA |
|---|---|---|
| Price | $32.06 | $13.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $34.00 | $20.40 |
| AVG Volume (30 Days) | 77.6K | ★ 197.0K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | 3.81 | ★ 29.93 |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $13.71 | $7.76 |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $43.12 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $26.31 | $6.44 |
| 52 Week High | $33.15 | $17.15 |
| Indicator | BCML | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 58.75 |
| Support Level | $27.59 | $13.19 |
| Resistance Level | $32.86 | $13.97 |
| Average True Range (ATR) | 0.74 | 0.83 |
| MACD | -0.02 | 0.31 |
| Stochastic Oscillator | 58.47 | 73.92 |
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses, and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services. The Company operates as one reportable segment: banking operations.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.